Regarding the safety of dust mite rush immunotherapy for allergic asthma, Omalizumab significantly reduces the incidence of SRs in high-risk populations (sIgE grades 3–6 and sIgE/T-IgE ≥10%), whereas it demonstrates limited efficacy in low-risk subgroups (sIgE grades 1–2 and sIgE/T-IgE <10%). The gene discussed is IGHE; the disease is allergic asthma.